TaigaNishihoriMD

Hematologic Oncology

Senior Member, Medical Director - BMT Program

Overview of Dr. Nishihori

Dr. Taiga Nishihori is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Hokkaido University Faculty of Medicine and has been in practice 18 years. Dr. Nishihori accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(650) 549-1077

Fax+1 813-745-6713

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2002 - 2006
Hokkaido University Faculty of MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2010 - 2026
CT State Medical License 2006 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Start of enrollment: 2014 Sep 23
Completed
Phase 1, Phase 2
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2016 Jun 10
Completed
Phase 2
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Start of enrollment: 2017 Jul 20
Completed
Phase 1, Phase 2
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jun 21
Withdrawn
Phase 1, Phase 2
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Contact
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) Start of enrollment: 2019 Nov 19
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2020 Nov 16
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

90 citations
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
Scott R. Goldsmith, Muhammad Bilal Abid, Jeffery J. Auletta, Asad Bashey, Amer Beitinjaneh
Blood. 2021-06-10
16 citations
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
Rima M Saliba, Amin M Alousi, Joseph Pidala, Mukta Arora, Stephen R Spellman
Transplantation and Cellular Therapy. 2022-10-01
43 citations
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury
Blood Advances. 2022-12-27

Journal Articles

Case Report Haploidentical Transplantation as a Promising Therapy for Relapsed Hemophagocytic Lymphohistiocytosis in an Older Adult Patient
Taiga Nishihori, Ernesto Ayala, ScienceDirect

Abstracts/Posters

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple ...
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Corre...
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Revi...
Taiga Nishihori, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

$Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA Approval$
Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA ApprovalJuly 24th, 2019

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment